FK506 suppresses hypoxia‑induced inflammation and protects tight junction function via the CaN‑NFATc1 signaling pathway in retinal microvascular epithelial cells

Hu,Yaguang; Yang,Boyu; Xu,Yue; Jiang,Li; Tsui,Ching-Kit; Liang,Xiaoling

doi:10.3892/mmr.2017.7475

FK506 suppresses hypoxia‑induced inflammation and protects tight junction function via the CaN‑NFATc1 signaling pathway in retinal microvascular epithelial cells

Authors:
- Yaguang Hu
- Boyu Yang
- Yue Xu
- Li Jiang
- Ching-Kit Tsui
- Xiaoling Liang
View Affiliations

Affiliations: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat‑sen University, Guangzhou, Guangdong 510000, P.R. China
Published online on: September 12, 2017 https://doi.org/10.3892/mmr.2017.7475
Pages: 6974-6980

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to identify whether FK506 suppresses hypoxia‑induced inflammation and protects tight junction function via the calcineurin‑nuclear factor of activated T‑cells 1 (CaN‑NFATc1) signaling pathway in mouse retinal microvascular endothelial cells (mRMECs). The mRMECs were treated with FK506 at different concentrations following the induction of hypoxia. Trans‑epithelial electrical resistance (TEER) and cell permeability were examined to measure the integrity of the tight junctions. The concentrations of inflammatory cytokines were measured using reverse transcription‑quantitative polymerase chain reaction analysis and enzyme‑linked immunosorbent assays. The protein expression levels of zonula occludens‑1 (ZO‑1) and nuclear factor of activated T‑cell 1 (NFATc1) were identified using immunofluorescent microscopy and western blot analysis. The TEER value was decreased following hypoxia, but increased following treatment with FK506 (1 and 10 µM) for 24 and 48 h. The protein expression of ZO‑1 was also increased following FK506 treatment for 24 h at 1 and 10 µM. By contrast, following treatment with FK506 (1 and 10 µM) for 24 and 48 h, the elevated cell permeability in the hypoxia group was significantly downregulated. Similarly, the concentrations of inflammatory cytokines, including cyclooxygenase‑2, inducible nitric oxide synthase, monocyte chemoattractant protein‑1, interleukin‑6, intercellular adhesion molecule‑1 and vascular cell adhesion molecule‑1, were downregulated following treatment with FK506 for 24 h at 1 and 10 µM. Following treatment with FK506, the level of total NFATc1 was downregulated and the level of phosphorylated NFATc1 was upregulated. Taken together, FK506 suppressed injury to the tight junctions and downregulated the expression of inflammatory cytokines in hypoxia‑induced mRMECs via the CaN‑NFATc1 signaling pathway. This suggests a potentially effective therapy for hypoxia‑induced retinal microangiopathy.

View Figures

View References

1	Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG and Issa P Charbel: Treatment of choroidal neovascularization due to angioid streaks: A comprehensive review. Retina. 33:1300–1314. 2013. View Article : Google Scholar : PubMed/NCBI
2	van Lookeren Campagne M, LeCouter J, Yaspan BL and Ye W: Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 232:151–164. 2014. View Article : Google Scholar : PubMed/NCBI
3	Mintz-Hittner HA, Kennedy KA and Chuang AZ: BEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 364:603–615. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kollias AN and Ulbig MW: Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int. 107:75–83. 2010.PubMed/NCBI
5	Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Alessiani M, Takaya S and Shapiro R: Liver, kidney and thoracic organ transplantation under FK 506. Ann Surg. 212:295–307. 1990. View Article : Google Scholar : PubMed/NCBI
6	Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B and Dignass AU: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol. 101:1048–1056. 2006. View Article : Google Scholar : PubMed/NCBI
7	Thestrup-Pedersen K: Tacrolimus treatment of atopic eczema/dermatitis syndrome. Curr Opin Allergy Clin Immunol. 3:359–362. 2003. View Article : Google Scholar : PubMed/NCBI
8	Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, Moutty MC and Fischer G: Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry. 45:15776–15784. 2006. View Article : Google Scholar : PubMed/NCBI
9	Haydon GH and Hayes PC: New immunosuppressive treatment in transplantation medicine. Baillieres Clin Gastroenterol. 8:455–464. 1994. View Article : Google Scholar : PubMed/NCBI
10	Tsuzuki S, Toyama-Sorimachi N, Kitamura F, Tobita Y and Miyasaka M: FK506 (tacrolimus) inhibits extravasation of lymphoid cells by abrogating VLA-4/VCAM-1 mediated transendothelial migration. FEBS Lett. 430:414–418. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kahan BD: Cyclosporine. N Engl J Med. 321:1725–1738. 1989. View Article : Google Scholar : PubMed/NCBI
12	Jacobson P, Uberti J, Davis W and Ratanatharathorn V: Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 22:217–225. 1998. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Zeyda M, Geyeregger R, Poglitsch M, Weichhart T, Zlabinger GJ, Koyasu S, Hörl WH, Stulnig TM, Watschinger B and Saemann MD: Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. J Leukoc Biol. 81:319–327. 2007. View Article : Google Scholar : PubMed/NCBI
15	Du S, Hiramatsu N, Hayakawa K, Kasai A, Okamura M, Huang T, Yao J, Takeda M, Araki I, Sawada N, et al: Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: Implication for unfolded protein response. J Immunol. 182:7201–7211. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yoshino T, Nakase H, Honzawa Y, Matsumura K, Yamamoto S, Takeda Y, Ueno S, Uza N, Masuda S, Inui K and Chiba T: Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis. 16:2022–2033. 2010. View Article : Google Scholar : PubMed/NCBI
17	Nakamura-Yanagidaira T, Takahashi Y, Sano K, Murata T and Hayashi T: Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. Mol Vis. 17:2157–2170. 2011.PubMed/NCBI
18	Xia W, Xia J, Zhang XF, Zhong L, Sun ZT and Wang YM: Inhibition of FK506 on the expression of vascular endothelial growth factor in retinal Müller cells cultured by high concentration glucose. Chin J Exp Ophthalmol. 32:998–1003. 2014.
19	Xiao ZX, Xie YY and Zhen RD: Effect of FK506 on injured vascular wall. Hainan Med J. 4:1–3. 2009.(In Chinese).
20	Larkin DF: Longitudinal changes to tight junction expression and endothelial cell integrity in a mouse model of sterile corneal inflammation. Invest Ophthalmol Vis Sci. 57:34852016. View Article : Google Scholar : PubMed/NCBI
21	Cannon AR, Akhtar S, Hammer AM, Morris NL, Javorski MJ, Li X, Kennedy RH, Gamelli RL and Choudhry MA: Effects of mesalamine treatment on gut barrier integrity after burn injury. J Burn Care Res. 37:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
22	Rao A, Luo C and Hogan PG: Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol. 15:707–747. 1997. View Article : Google Scholar : PubMed/NCBI
23	Hogan PG, Chen L, Nardone J and Rao A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 17:2205–2232. 2003. View Article : Google Scholar : PubMed/NCBI
24	Mancini M and Toker A: NFAT proteins: Emerging roles in cancer progression. Nat Rev Cancer. 9:810–820. 2009. View Article : Google Scholar : PubMed/NCBI
25	Chang CP, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, Graef IA and Crabtree GR: A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell. 118:649–663. 2004. View Article : Google Scholar : PubMed/NCBI
26	Graef IA, Chen F, Chen L, Kuo A and Crabtree GR: Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell. 105:863–875. 2001. View Article : Google Scholar : PubMed/NCBI
27	Bretz CA, Savage S, Capozzi M and Penn JS: The role of the NFAT signaling pathway in retinal neovascularization. Invest Ophthalmol Vis Sci. 54:7020–7027. 2013. View Article : Google Scholar : PubMed/NCBI
28	Minami T, Jiang S, Schadler K, Suehiro J, Osawa T, Oike Y, Miura M, Naito M, Kodama T and Ryeom S: The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep. 4:709–723. 2013. View Article : Google Scholar : PubMed/NCBI